maze therapeutics | Maze Therapeutics

Keyword	CPC	PCC	Volume	Score	Length of keyword
maze therapeutics	1.6	0.6	1964	62	17
maze	1.08	0.4	7337	37	4
therapeutics	1.55	0.7	4891	46	12

Keyword	CPC	PCC	Volume	Score
maze therapeutics	0.51	0.2	493	91
maze therapeutics stock	0.32	0.8	294	63
maze therapeutics careers	0.67	0.7	3461	45
maze therapeutics pompe	0.6	0.2	8241	59
maze therapeutics pipeline	0.51	0.9	1134	58
maze therapeutics email format	1.42	0.2	809	30
maze therapeutics ipo	1.89	0.3	4909	8
maze therapeutics logo	1.3	0.8	1556	57
maze therapeutics news	1.23	0.8	9641	54
maze therapeutics apol1	1.36	0.7	4181	47
maze therapeutics sanofi	1.77	0.8	6247	63
maze therapeutics address	1.77	0.3	2357	47
maze therapeutics funding	0.24	0.9	2055	31
maze therapeutics stock price	0.99	0.2	4133	3
maze therapeutics inc	0.8	0.4	2413	83
gys1 maze therapeutics	1.03	0.4	7883	49

Search Results related to maze therapeutics on Search Engine

Maze Therapeutics | Genetic Navigators
mazetx.com

https://mazetx.com/

WEBMaze Therapeutics is developing medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants and help protect the kidneys from disease. Our first such precision medicine program is directed against APOL1 kidney disease.

DA: 11 PA: 32 MOZ Rank: 27

About Us | Maze Therapeutics
mazetx.com

https://mazetx.com/about-us/

WEBAbout Us | Maze Therapeutics. harnessing the power of genetics to transform the lives of patients. In the summer of 2018, we had an idea. A big idea, inspired by the recent dramatic advances in the field of genetics and the significant gaps in translating those into medicines.

DA: 34 PA: 42 MOZ Rank: 18

Our Programs | Maze Therapeutics
mazetx.com

https://mazetx.com/our-programs/

WEBUtilizing Maze Compass™, Maze is harnessing the power of human genetics to transform the lives of patients. We are building a broad portfolio of wholly owned and partnered programs, with a focus on genetically informed therapies for common diseases such as chronic kidney disease.

DA: 12 PA: 52 MOZ Rank: 71

Our Approach | Maze Therapeutics
mazetx.com

https://mazetx.com/our-approach/

WEBOur strategy focuses on advancing precision medicines to address common diseases across renal and cardio-metabolic indications. To do this, we are applying insights in genetics, combined with our area expertise and Compass™ platform to maximize the long-term impact we can have on worldwide human health.

DA: 32 PA: 12 MOZ Rank: 72

News & Press | Maze Therapeutics
mazetx.com

https://mazetx.com/news-press/

WEBMay 1, 2023 · Biotech Startup Maze Therapeutics Strikes $750 Million Deal With Sanofi. May 1, 2023. Sanofi strikes a $150M deal for Maze’s Pompe disease drug. May 1, 2023. Sanofi’s next chapter in Pompe: $150M for Maze pact as …

DA: 68 PA: 74 MOZ Rank: 6

Maze Therapeutics Announces Exclusive Worldwide License …
mazetx.com

https://mazetx.com/maze-therapeutics-announces-new-clinical-data-supporting-mze001-as-a-potential-treatment-for-pompe-disease-2/

WEBMay 1, 2023 · SOUTH SAN FRANCISCO, CA., May 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the signing of an exclusive worldwide license agreement with Sanofi (Nasdaq: SNY) for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is …

DA: 20 PA: 96 MOZ Rank: 5

Maze Therapeutics | LinkedIn
linkedin.com

https://www.linkedin.com/company/mazetx

WEBMaze Therapeutics | 17,173 followers on LinkedIn. At Maze, we envision a world where genetic insights inspire new medicines. | Maze Therapeutics is translating novel genetic insights into ...

DA: 73 PA: 58 MOZ Rank: 34

Maze Therapeutics Presents New Preclinical Data Supporting …
mazetx.com

https://mazetx.com/maze-therapeutics-presents-new-preclinical-data-supporting-advancement-of-mze001-as-a-potential-treatment-for-pompe-disease/

WEBFeb 10, 2022 · SOUTH SAN FRANCISCO, CA., Feb. 10, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle …

DA: 85 PA: 80 MOZ Rank: 88

Maze Therapeutics Reveals Its Initial Three Lead Programs …
mazetx.com

https://mazetx.com/maze-therapeutics-reveals-its-initial-three-lead-programs-targeting-underlying-genetic-drivers-of-life-threatening-diseases/

WEBMar 23, 2021 · SOUTH SAN FRANCISCO, CALIF., March 23, 2021 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today revealed its first three lead therapeutic candidates in the company’s wholly owned pipeline. The candidates include: An oral therapy targeting GYS1 for the treatment of Pompe disease.

DA: 77 PA: 80 MOZ Rank: 77

Maze Therapeutics Announces FDA Orphan Drug Designation …
businesswire.com

https://www.businesswire.com/news/home/20220831005268/en/Maze-Therapeutics-Announces-FDA-Orphan-Drug-Designation-Granted-to-MZE001-for-the-Treatment-of-Pompe-Disease

WEBAug 31, 2022 · Maze Therapeutics is a clinical-stage biopharmaceutical company applying advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline...

DA: 60 PA: 50 MOZ Rank: 38